Executives reflect on the major shifts in the industry in the last 15 years and the evolving market dynamics that will impact global communication. You may also read the Executive Perspective article in the March issue of PharmaVOICE, using the link below.

Enjoy the Executive Forum.

Enjoy this visual recap of the 2018 PharmaVOICE 100 Celebration. Dozens of photos, video clips, and interviews showcase the amazing talent in our industry. This year’s core topic was Transformation.

This video explains what the PharmaVOICE Healthy Opinions webcast program is all about.

This white board “Explainer” video describes how you can re-purpose one piece of content for numerous other uses. PharmaVOICE has the expertise and knowledge to help you.

Dr. Deieso and Ms. Johnston discuss how Precision Medicine is impacting clinical trials, the opportunities provided by Precision Medicine, their partnership with Informed DNA, and the evolution of the Center for Genetics and Precision Medicine in Clinical Trials.

Mr. Alasso discusses the biggest challenges for sponsors and CROs in exploiting new technology in clinical research, enhancing the patient experience, the impact of technology on clinical trials in the next 3-5 years, and the biggest trend seen at DIA.

Todd Phillips talks about the importance or Patient-reported Outcomes (PROs), therapeutic areas using PROs, FDA guidances on PROs, and how pharma can incorporate PROs into their development programs.

Ms. Verst discusses how IQVIA addresses pain points in clinical research, using Real-world Data, advanced analytics, and machine learning, how technology enables collaboration, and how rare disease is driving productivity in clinical trials.

Dr. Stemhagen discusses using a Real-world Evidence strategy in clinical development, the practical applications of RWE, the long-term results of RWE, and trends seen while at DIA.

Mr. McGrath discusses MRN’s growth in the industry due to a patient-centric approach to recruitment and retention, the emergence of virtual trials, the inherent challenges of patient recruitment, and their partnership with Patient Primary to provide a patient travel support … Read More »

Ms. Kapoor talks about Cognizant’s Shared Investigator Platform, how it ties in with TransCelerate members, the qualitative and quantitative benefits of sponsors and sites using the platform, and interesting trends seen while at DIA.

Mr. Kalim discusses their two major acquisitions, their Smarter Testing for Oncology services, the ACM rebranding, and what they looked for at DIA this year.

Ms. Kent discusses the role of technology in the life-sciences, employing patient-centric clinical trials, and mentoring women in the industry.

Ms. Dilworth discusses the key challenges in operationalizing rare disease trials, the most exciting trends in rare disease trials, and what drives her to work in the rare disease space.

Mr. Damji discusses exciting trends in clinical trials, how AI and Natural Language Understanding will impact drug development, and optimizing the clinical journey using validated cloud-based solutions.

Dr. Morimoto discusses scientific breakthroughs and their impact on drug development efforts, expertise in vaccine research, and using biomarkers in clinical research.

Dr. Li talks about supporting the Life Sciences industry, the clinical trials ecosystem, and leveraging Real World Data in clinical research.

Mr. Benton discusses the evolution of the CRO industry, the sustainability of the current M&A model, what sponsors should look for in a CRO partner, how they maintain their company culture, and their vision for the future.

Mr. Kleger discusses alleviating the technology burden on clinical trial sites, the future of clinical trials, and technology trends and strategies for clinical research.

Mr. Monteleone discusses challenges CROs face working with sponsors, the importance of focusing on regulatory and strategic development issues, opportunities for small/mid-sized CROs, critical aspects of a good partnership, and understanding the dynamic changes in technology … Read More »

Mr. Duffy discusses trending skills in the life sciences industry, the gig economy, and attracting the best and brightest employees.

Mr. Casarella discusses why large clinical development service providers are slow to adapt to changes in technology, the impact of ICH E6(R2), optimal strategies for talent acquisition, and studies for oncology and rare diseases.

Mr. Hayashi discusses LabConnect’s collaboration with Symphony Clinical Research, hot topics at DIA, and technology as an industry connector. Mr. Hayhew discusses trends and issues related to PBMC isolation within clinical trials.

This is a PharmaVOICE-exclusive PodcastPlus version of the original audio podcast. It is enhanced with visuals to provide additional content. Advertising agencies have always been known by their ability to create amazingly creative campaigns. Its how they’ve built reputation … Read More »

Bhaskar Sambasivan discusses how executives can leverage digital technologies, key areas of focus for Life Sciences companies, managing numerous aspects in the move towards patient-centricity, and how platforms can unlock new revenue streams and provide cost savings.

Jim Corrigan discusses the risks associated with clinical trials, clearing the hurdle of paper in clinical research, the most promising and exciting advancements in the eclinical space, where the eclinical space will be five years from now, and the new era of collaboration.

Richard Scheyer discusses the importance of patient-centricity in rare disease studies, the benefits of customized studies, connecting with key investigators, and the increased interest in rare diseases.

Matthew J. Neal discusses the biggest challenge that regulatory and clinical systems need to address, how technology can be used in this cause, how global health authorities are dealing with these issues, and how data is at the center of the movement towards patient-centrici … Read More »

Robert A. Carlson, MD discusses digital pathology as it relates to clinical trials, how patients benefit, as well as the cause and effect of the diminishing number of pathologists.

Jeff Wendel discusses how an IRB can streamline study startups, trends in regulatory and site identification, and working with academic medical centers to insure compliance with sIRB policy.

Staci McDonald, PharmD discusses how Celerion’s business is changing with the emergence of biosimilar drugs, why biosimilar developers choose to work with Celerion, and what they have learned in the course of their biosimilar research.

Simon J. Griffin discusses the merits of adding a Cloud-based video EEG component to a trial protocol, which therapeutic categories benefit the most from this, and how a Cloud strategy can improve recruitment and randomization goals.

David Connelly discusses Cmed’s new Encapsia product, its benefits in the clinical trials process, how sponsors can use it, and its current availability.

Andrew Cassel discusses Machine Learning technology, and the practical applications of predictive modeling and genomics in clinical trials.

Judith Ng-Cashin discusses running clinical trials for rare diseases, including critical factors, engaging patients, additional stakeholders, and the growing amount of clinical research in the rare disease space.

Bill Byrom discusses Bring-your-own-device (BYOD) adoption by patients in clinical trials, industry concerns, supporting evidence in favor of BYOD adoption, and thoughts on the next frontier in clinical trials.

Eric Delente discusses how eConsent differs from the traditional informed consent procedures, the barriers keeping some organizations from converting to digital, lessons learned regarding eConsent, and how eConsent can make monitoring easier.

Donald A. Deieso PhD discusses the changing landscape for clinical and IRB services, transformative improvements in clinical research, the recent acquisitions by WIRB-Copernicus Group, and how their alliance with Huron is improving the efficiency of clinical trials.

Alastair MacDonald and Janet Baldwin discuss why Real World Evidence (RWE) is important today, insights on late-stage research, when companies should start thinking about RWE generation, recommendations on identifying and collecting RWE, and the future of RWE.

Scott Gray discusses why recruiting a diverse patient base in clinical trials is important, the barriers to achieving patient diversity, tips for ensuring greater diversity among patients, the ROI for such practices, and an example of one of his success stories.

Jignesh Patel discusses adaptive clinical trials, how this process relates to the FDA and the 21st Century Cures Act, its benefits and limitations, and when it should be used in clinical research.

Kevin Duffy discusses talent in the Life Sciences and Healthcare space, how to keep millennials on staff, and the impact of technology on talent.

Jason Casarella discusses trends in the CRO market, challenges sponsors face today, how the industry is reponding to these challenges, and the rate of collaboration between companies in the industry.

Nicholas Kenny discusses innovative trial designs, collaboration in clinical research, the impact of collaboration to INC Research, sites, and sponsors, and the evolution of immunotherapy and combination trials.

Peter Benton discusses current trends in the CRO space, how Worldwide Clinical Trials is responding to these trends, challenges sponsors currently face, what the “Cure for the Common CRO” means, how to attract the best new talent through cultural changes, and how to address … Read More »

Andrew Schachter discusses how small/mid-sized life sciences organizaions select EDC vendors, the concept of “Unified” in an eClinical suite, the pain points for end-users, and Axiom’s Fusion eClinical Suite.

Abhishek Shankar discusses the value of patient-centricity and and how the cloud is transforming operations in the life-sciences industry.